PharmaSGP Holding Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Peter Gerckens
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.1yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 4.9yrs |
Recent management updates
Recent updates
PharmaSGP Holding's (ETR:PSG) Performance Is Even Better Than Its Earnings Suggest
Dec 06
Shareholders Will Be Pleased With The Quality of PharmaSGP Holding's (ETR:PSG) Earnings
May 06Some Shareholders Feeling Restless Over PharmaSGP Holding SE's (ETR:PSG) P/E Ratio
Mar 02PharmaSGP Holding SE Just Beat Revenue Estimates By 25%
Dec 02One Analyst Just Shaved Their PharmaSGP Holding SE (ETR:PSG) Forecasts Dramatically
Feb 16
We Think PharmaSGP Holding's (ETR:PSG) Statutory Profit Might Understate Its Earnings Potential
Jan 26Do Institutions Own PharmaSGP Holding SE (ETR:PSG) Shares?
Dec 04CEO
Peter Gerckens (37 yo)
1.1yrs
Tenure
Mr. Peter Gerckens serves as Member of Management Board at PharmaSGP Holding SE from 2024 and serves as Chief Executive Officer since January 1, 2025 and served as its Chief Commercial Officer from 2024 un...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of the Supervisory Board | 4.7yrs | €50.00k | no data | |
| Deputy Chairwoman of the Supervisory Board | 4.9yrs | no data | 48.95% € 152.6m | |
| Chairman of the Supervisory Board | 4.9yrs | no data | no data |
4.9yrs
Average Tenure
49yo
Average Age
Experienced Board: PSG's board of directors are considered experienced (4.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 06:06 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaSGP Holding SE is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gerhard Orgonas | Berenberg |
| Charles Weston | RBC Capital Markets |
| Jack Reynolds-Clark | RBC Capital Markets |